Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraventricular Pemetrexed and Nivolumab for Refractory NSCLC with Leptomeningeal Metastases
NCT06901817Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and nivolumab in leptomeningeal metastases (LM), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Adverse Event at 30 days. Started Mar 2025; status: recruiting.
02
Drugs
pemetrexednivolumab
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT06901817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901817.